Advertisement
Canada markets close in 5 hours 31 minutes
  • S&P/TSX

    22,365.28
    -102.88 (-0.46%)
     
  • S&P 500

    5,321.23
    -0.18 (-0.00%)
     
  • DOW

    39,881.06
    +8.07 (+0.02%)
     
  • CAD/USD

    0.7315
    -0.0020 (-0.28%)
     
  • CRUDE OIL

    77.55
    -1.11 (-1.41%)
     
  • Bitcoin CAD

    95,080.41
    -1,342.00 (-1.39%)
     
  • CMC Crypto 200

    1,503.59
    -22.83 (-1.50%)
     
  • GOLD FUTURES

    2,392.80
    -33.10 (-1.36%)
     
  • RUSSELL 2000

    2,092.58
    -5.78 (-0.28%)
     
  • 10-Yr Bond

    4.4280
    +0.0140 (+0.32%)
     
  • NASDAQ

    16,840.72
    +8.09 (+0.05%)
     
  • VOLATILITY

    11.93
    +0.07 (+0.59%)
     
  • FTSE

    8,354.82
    -61.63 (-0.73%)
     
  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     
  • CAD/EUR

    0.6747
    -0.0007 (-0.10%)
     

DIAGNOS Provides Additional Information to the Closing of Private Placement

DIAGNOS Inc.
DIAGNOS Inc.

BROSSARD, Quebec, Dec. 15, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that in connection with the closing of the private placement announced on December 12, 2022, the Corporation paid a cash commission of $9,000 to one qualified person (“Finder”) and issued 40,909 finder’s warrants to the Finder. Each finder’s warrant entitles the Finder to purchase one Share at an exercise price of $0.26 per Share for a period of 18 months ending June 9, 2024.

The private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation.

All monies quoted in this press release shall be stated and paid in lawful money of Canada.

ADVERTISEMENT

This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca